Skip to main content

Table 1 Baseline Demographics and Clinical Features of CM

From: Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Variable

Enrolled Population N = 716

Mean (SD) age, y

43.0 (11.3)

Female, n (%)

607 (84.8)

Race, n (%)

 Caucasian

582 (81.3)

 Asian

89 (12.4)

 African American/black

41 (5.7)

 Other

4 (0.6)

Mean (SD) height, cm

165.8 (8.7)

Mean (SD) weight, kg

75.6 (19.8)

Mean (SD) BMI, kg/m2

27.4 (6.4)

Mean (SD) age of onset of CM, y

32.5 (13.7)

Mean (SD) time since onset of CM, y

10.6 (11.0)

Family history of migraine, yes, n (%)

449 (62.7)

Headache-related history,a n (%)

 Sleep disorder

210 (29.3)

 Smoking

150 (20.9)

 Head trauma

74 (10.3)

 Childhood abuse/maltreatment

50 (7.0)

Severity of pain during headache, n (%)

 Mild

3 (0.4)

 Moderate

296 (41.3)

 Severe

417 (58.2)

Pain on one or both sides of head, n (%)

 One

382 (53.4)

 Both

334 (46.6)

Type of head pain, n (%)

 Throbbing or pulsing

507 (70.8)

 Pressing or squeezing

170 (23.7)

 Neither throbbing, pulsing, pressing, squeezing

39 (5.4)

Severity of neck pain or stiffness, n (%)

 Mild

70 (9.8)

 Moderate

331 (46.2)

 Severe

157 (21.9)

 None

158 (22.1)

Other headache features, n (%)

 Sensitivity to light

658 (91.9)

 Physical activity worsens headache

642 (89.7)

 Sensitivity to noise

639 (89.2)

 Nausea with headache

583 (81.4)

 Vomiting with headache

295 (41.2)

 Cutaneous allodynia

290 (40.5)

Mean (SD) headache daysb

22.0 (4.8)

Mean (SD) moderate or severe headache daysb

18.0 (5.7)

Mean (SD) HIT-6 total scorec

64.7 (4.8)

  1. CM chronic migraine, HIT-6 6-item Headache Impact Test
  2. aPatients may be counted in > 1 category
  3. bHeadache days per 28 d in the analysis population (n = 715); includes 25 patients who reported < 15 headache days per 28 d at baseline
  4. cIn the analysis population (n = 715)